[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447193":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Esperion Therapeutics, Inc.","INDUSTRY",null,[9,15],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Bempedoic Acid","Bempedoic Acid 180 MG",[14],"Nexletol",{"type":10,"name":16,"description":17,"armGroupLabels":7,"otherNames":18},"Bempedoic Acid \u002F Ezetimibe","Bempedoic Acid 180 MG \u002F Ezetimibe 10 MG",[19],"Nexlizet",[21],{"name":22,"affiliation":23,"role":24},"Christine Broestl, MS","Esperion Therapuetics","STUDY_DIRECTOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":7,"email":29},"CONTACT","1 833 377 7633 (Option 5)","Bempedoic.Acid.PSP@ppd.com",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":7},"Evidera, PPD business unit","RECRUITING","Morrisville","North Carolina","27560","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-78.82556,35.82348,{"lat":43,"lon":42},{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100447193","bempedoic-acid-pregnancy-surveillance-program-100447193",false,"NCT05103254","Bempedoic Acid Pregnancy Surveillance Program","A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid\u002FEzetimibe Fixed Combination Drug Product (FCDP) During Pregnancy","Inclusion Criteria:\n\nExposure to at least 1 dose of bempedoic acid or bempedoic acid\u002Fezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \\[LMP\\] to pregnancy outcome\n\nExclusion Criteria:","FEMALE","18 Years",{"count":57,"type":58},20,"ESTIMATED","OBSERVATIONAL","Bempedoic acid pregnancy surveillance program",[62,63],"Pregnancy","Hyperlipidemias",[65],"bempedoic acid","2024-05-15",{"date":68,"type":69},"2024-05-17","ACTUAL",{"date":71,"type":69},"2021-09-01",{"date":73,"type":58},"2032-05",{"name":5,"class":6},1]